Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Interferon α/β Enhances the Cytotoxic Response of MEK Inhibition in Melanoma.

Molecular cell - 5 Mar 2015

Litvin Oren, Schwartz Sarit, Wan Zhenmao, Schild Tanya, Rocco Mark, Oh Nul Loren, Chen Bo-Juen, Goddard Noel, Pratilas Christine, Pe'er Dana

Abstract excerpt

Drugs that inhibit the MAPK pathway have therapeutic benefit in melanoma, but responses vary between patients, for reasons that are still largely unknown. Here we aim at explaining this variability using pre- and post-MEK inhibition transcriptional profiles in a panel of melanoma cell lines. We f...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Benzamides
Share to Cell Survival
Share to Interferon-alpha

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Interferon-beta

Share to MAP Kinase Signaling System

Share to Melanoma

Share to Microphthalmia-Associated Transcription Factor

Share to STAT1 Transcription Factor

Source

Open in PubMed Open full text

Identifiers

PMID: 25684207
DOI: 10.1016/j.molcel.2014.12.030
PMCID: PMC4355234

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25684207-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Interferon α/β Enhances the Cytotoxic Response of MEK Inhibition in Melanoma.PMID 25684207Read ↗

Activities of multiple cancer-related pathways are associated with BRAF mutation and predict the resistance to BRAF/MEK inhibitors in melanoma cells.Semantic proximity Read ↗

Cancer pathway connectivity resolved by drug perturbation and RNA sequencingSemantic proximity Read ↗

A transcriptional MAPK Pathway Activity Score (MPAS) is a clinically relevant biomarker in multiple cancer typesSemantic proximity Read ↗

Personalized logical models to investigate cancer response to BRAF treatments in melanomas and colorectal cancersSemantic proximity Read ↗

Systems biology analysis of mitogen activated protein kinase inhibitor resistance in malignant melanomaSemantic proximity Read ↗

Perturbation biology links temporal protein changes to drug responses in a melanoma cell lineSemantic proximity Read ↗

Copy Number Loss of the Interferon Gene Cluster in Melanomas Is Linked to Reduced T Cell Infiltrate and Poor Patient PrognosisSemantic proximity Read ↗

Epigenetic modulation reveals differentiation state specificity of oncogene addiction.Semantic proximity Read ↗

Epigenetic modulation reveals differentiation state specificity of oncogene addictionSemantic proximity Read ↗

Overcoming Resistance to BRAF <sup>V600E</sup> Inhibition in Melanoma by Deciphering and Targeting Personalized Protein Network AlterationsSemantic proximity Read ↗

Systematic review and network meta-analysis of drug combinations suggested by machine learning on genes and proteins, with the aim of improving the effectiveness of Ipilimumab in treating MelanomaSemantic proximity Read ↗

The unfolded protein response impacts melanoma progression by enhancing FGF expression and can be antagonized by a chemical chaperone.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.